OPM Integrated Into the LRRK2 Investigative Therapeutics Exchange Program From the Michael J. Fox Foundation for Parkinson’s Research

About this update from Oncodesign Precision Medicine S.a.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/efe76dae3a44f10af285b97e354e6791"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mkZYnyTHW7qMttG41SIZiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/efe76dae3a44f10af285b97e354e6791","width":480,"height":320}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"OPM will contribute its unique expertise in kinase inhibitor development and its Nanocyclix®-derived compound OPM-201 to the LITE program","length":137,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":137,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"OPM will leverage the LITE consortium to accelerate the clinical development of OPM-201, strengthen the credibility of the drug candidate, and expand opportunities for fruitful collaborations","length":191,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":191,"olType":false},{"type":"text","content":"DIJON, France, September 25, 2025--(BUSINESS WIRE)--Regulatory News:","length":68,"tagName":"p"},{"type":"text","content":"Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces it has joined The Michael J. Fox Foundation for Parkinson’s Research’s program the (MJFF) LRRK2 Investigative Therapeutics Exchange (LITE).","length":348,"tagName":"p"},{"type":"text","content":"The participation of OPM to The Michael J. Fox Foundation for Parkinson’s Research (MJFF) program the LRRK2 Investigative Therapeutics Exchange (LITE) follows the reacquisition of the rights to its OPM-201 program from Servier in December 2024. As a reminder, OPM and Servier have jointly developed OPM-201 a novel small molecule inhibitor of LRRK2 kinase (Leucine-Rich Repeat Kinase 2), a key therapeutic target in Parkinson’s disease. This selective, potent, and orally active compound demonstrates the ability to block LRRK2 phosphorylation in the brain without observable side effects at effective doses. Initially developed in familial forms of Parkinson’s linked to L...

More updates from Oncodesign Precision Medicine S.a.